Disease · MONDO_0004703
bladder carcinoma in situ
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. bladder carcinoma in situ. Diseases, record MONDO_0004703. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004703
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
bladder flat CIS, bladder flat carcinoma in situ, carcinoma in situ of bladder, carcinoma in situ of the urinary bladder, carcinoma in situ of urinary bladder, flat CIS of the bladder, flat CIS of the urinary bladder, flat carcinoma in situ of the bladder, flat carcinoma in situ of the urinary bladder, high grade bladder Intraurothelial neoplasia, stage 0 urinary bladder carcinoma, stage 0is bladder cancer, stage 0is bladder carcinoma, stage 0is bladder urothelial cancer, stage 0is bladder urothelial carcinoma, stage 0is bladder urothelial carcinoma aJCC v6, stage 0is bladder urothelial carcinoma aJCC v6 and v7, stage 0is bladder urothelial carcinoma aJCC v7, stage 0is carcinoma of bladder, stage 0is carcinoma of the bladder, stage 0is carcinoma of the urinary bladder, stage 0is carcinoma of urinary bladder, stage 0is urinary bladder carcinoma, urinary bladder carcinoma in situ, urinary bladder flat CIS, urinary bladder flat carcinoma in situ, urinary bladder in situ carcinoma
- Open Targets
Drugs16
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BCG VACCINE | CHEMBL2108905 | Vaccine component | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| VALRUBICIN | CHEMBL1096885 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| BCG LIVE | CHEMBL2108020 | Phase 3 | ClinicalTrials.gov | 2 | 2 | 0 | Drugs and targets | |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| DURVALUMAB | CHEMBL3301587 | Antibody | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| APAZIQUONE | CHEMBL73822 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FAVEZELIMAB | CHEMBL4297784 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MITOMYCIN | CHEMBL105 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PEMBROLIZUMAB | CHEMBL3137343 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| VIBOSTOLIMAB | CHEMBL4297785 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 16
See all 16 drugsTargets37
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CD274 | Programmed cell death 1 ligand 1 | 1 | Programmed cell death 1 ligand 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| CTLA4 | Cytotoxic T-lymphocyte protein 4 | 1 | Cytotoxic T-lymphocyte protein 4 inhibitor | Phase 1/2 | https://conductscience.org/library/genes/1493 | Drugs and targets |
| EFNB2 | Ephrin-B2 | 1 | Ephrin-B2 inhibitor | Phase 1 | https://conductscience.org/library/genes/1948 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 1 | FK506-binding protein 1A inhibitor | Phase 1/2 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| LAG3 | Lymphocyte activation gene 3 protein | 1 | Lymphocyte activation gene 3 protein inhibitor | Phase 2 | https://conductscience.org/library/genes/3902 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 1 | Programmed cell death protein 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| POLA1 | DNA polymerase (alpha/delta/epsilon) | 1 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 1/2 | https://conductscience.org/library/genes/5422 | Drugs and targets |
| POLA2 | DNA polymerase (alpha/delta/epsilon) | 1 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 1/2 | https://conductscience.org/library/genes/23649 | Drugs and targets |
| POLD1 | DNA polymerase (alpha/delta/epsilon) | 1 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 1/2 | https://conductscience.org/library/genes/5424 | Drugs and targets |
| POLD2 | DNA polymerase (alpha/delta/epsilon) | 1 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 1/2 | https://conductscience.org/library/genes/5425 | Drugs and targets |
1 to 10 of 37
See all 37 targetsTrials14
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01259063 | RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder | Phase 1/2 | 33 | 2018-03-13 | Bladder Cancer | EVEROLIMUS, GEMCITABINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02901548 | Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder | Phase 2 | 17 | 2021-06-11 | Carcinoma in Situ of Bladder, Bladder Cancer | DURVALUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01310803 | Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder | Phase 3 | 1 | 2014-10-22 | Carcinoma in Situ, Transitional Cell Carcinoma, Non-muscle Invasive Bladder Cancer | VALRUBICIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02138734 | A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer | Phase 1/2 | 369 | Non-muscle Invasive Bladder Cancer | BCG VACCINE, INBAKICEPT, NOGAPENDEKIN ALFA | Its record names the disease | ClinicalTrials.gov | |
| NCT02625961 | Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057) | Phase 2 | 296 | Bladder Cancer | FAVEZELIMAB, PEMBROLIZUMAB, VIBOSTOLIMAB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT05024773 | Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID) | Phase 3 | 130 | Bladder Carcinoma in Situ (CIS) | PACLITAXEL | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00023842 | BCG With or Without Mitomycin in Treating Patients With Bladder Cancer | Phase 2 | 97 | Bladder Cancer | BCG VACCINE, MITOMYCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01316874 | Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG) | Phase 2/3 | 90 | Carcinoma in Situ, Bladder Cancer | VALRUBICIN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00003129 | Chemotherapy in Treating Patients With Early-Stage Bladder Cancer | Phase 2 | 75 | Bladder Cancer | VALRUBICIN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00141531 | Phase II Trial of EOquin in High-risk Superficial Bladder Cancer | Phase 2 | 53 | Bladder Neoplasms | APAZIQUONE | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 14
See all 14 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials7
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004703
GET https://conductscience.org/api/diseases/v1/MONDO_0004703/targets?page=2